Cure8 research brief
The paper reports a novel small molecule (CA-23) that directly antagonizes CD28, reducing pathogenic T cell responses in preclinical IBD models and in cells from IBD donors. If validated, this represents a mechanistically different approach to modulating T cell costimulation that may spare regulatory T cell function.
Researchers, translational scientists, and clinicians interested in IBD immunology and new therapeutic strategies
The study used a screening platform to identify CA-23, showed it binds CD28 (not CD80/86 or CTLA-4), and demonstrated anti-inflammatory effects in mouse colitis models and in human blood/PBMC samples from IBD donors.
The authors report that CA-23 reached the colon and mesenteric lymph nodes, lowered histologic injury and Th1/Th17 responses in a T cell transfer colitis model, and preserved Treg suppressive activity in co-cultures where abatacept did not. The findings are preclinical and reported in a preprint abstract.
This work supports further investigation but does not establish safety or efficacy in humans. Clinical trials would be needed before any use in patients.
Preclinical and ex vivo findings in a preprint should not be interpreted as clinical evidence. Peer review and clinical trials are required to assess safety and efficacy in people.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
CAR-based cellular therapies could offer a new way to reset immune responses in some forms of IBD, potentially helping patients who do not respond to existing biologics or small molecules.
Colon-targeted delivery systems aim to concentrate drugs in the colon, which could improve effectiveness and reduce systemic side effects for IBD and colorectal cancer treatments. Understanding these approaches helps...
Researchers are exploring a way to deliver biologic drugs directly in the gut using engineered B cells that become long-lived plasma cells. If successful, this could allow sustained, localized anti-inflammatory protein...
